Recent News

• 03.31.2026 - Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
• 03.27.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 03.16.2026 - Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
• 03.16.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 03.13.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 03.11.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 03.06.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 03.05.2026 - Oculis to Participate in Upcoming Investor Conferences
• 03.05.2026 - Oculis Publishes 2025 Consolidated Financial Statements
• 03.04.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Recent Filings

• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.09.2026 - 144 Report of proposed sale of securities
• 03.04.2026 - EX-99.1 EX-99.1
• 03.04.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.04.2026 - F-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 03.04.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.03.2026 - EX-99.1 EX-99.1